|Day's Range||1.90 - 2.00|
|52 Week Range||1.10 - 2.47|
|PE Ratio (TTM)||-4.73|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On March 17, Resverlogix Corp. (RVX.TO) posted its financial statements and management discussion and analysis for its third quarter of fiscal year 2017 ending January 31, 2016. The company reported no revenues and a net loss of ($13.0) million or ($0.12) per share. This compares to our estimates also of zero revenues and a net loss of ($7.3) million or ($0.07) per share. Total operational expenses for 3Q:17 were $13.0 million, increasing from $8.9 million in the same quarter of the prior year. Second quarter research & development expenses rose 120%, while general & administrative increased 21%. Costs for the Renal PK and the BETonMACE clinical trials related to recruiting and clinical supply shipments were important drivers behind the increase. General and administrative costs fell just below $1.0 million up 21% from $0.8 million as a payment for a cardiovascular continuing education grant was made. Net finance costs fell in 3Q primarily due to lower loss from change in value of royalty preferred shares offset by higher foreign exchange loss and interest accretion. The warrant liability shifted from a gain in 3Q:16 to a slight loss in 3Q:17 due to the increase in stock price.
Categories: Yahoo Finance Get free summary analysis Resverlogix Corp. reports financial results for the quarter ended October 31, 2016. Analysis Summary numbers: Revenues of CAD 0 million, Net Earnings of CAD -19.88 million. The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless. RVX-CA‘s book value ... Read more (Read more...)
On July 28, 2016, Resverlogix Corp. (RVX.TO) filed financial results for the fiscal year ending April 30, 2016 with the Alberta Securities Commission. The company reported no revenues and a net loss of ($19.7) million or ($0.20) per share. This compares to our estimates also of zero revenues and a net loss of ($16.6) million or ($0.16) per share. Total operational expenses for FY:16 were $20.0 million, increasing from the $8.5 million spent in the prior year. Full-year research & development expenses rose substantially, while general & administrative remained flat, with costs related to the BETonMACE clinical trial driving the majority of the increase. The study’s primary goal is to confirm the favorable pharmacokinetic traits that have been observed in other apabetalone trials. The study is being conducted in New Zealand and expects to post results in the second half of 2016, after which additional renal impairment and dialysis trials will proceed based on favorable data. We hope to see a Phase 2 trial begin shortly after the completion of the data analysis and Resverlogix could potentially obtain approval in a renal indication under an orphan designation prior to an approval for high-risk cardiovascular disease.